Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 1,380 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Diabetes Diagnosis Clear all
Recruiting Phase 2 Interventional

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

NCT07271186
View directory record Official record
Conditions
Diabetic Kidney Disease (DKD)
Interventions
ALN-ANG3, Evinacumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
58
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Huntington Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 2 Interventional

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

NCT06131372
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes, Obesity
Interventions
Cagrilintide, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
25
States / cities
Concord, California • Fresno, California • Palm Springs, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Not applicable Interventional

NYULMC CareSmarts Pilot

NCT02726217
View directory record Official record
Conditions
Diabetes, Type 2 Diabetes (T2D)
Interventions
CareSmarts Mobile Health Diabetes Program, Standard of Care Reminders and Self Assessments
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Not applicable Interventional Results available

Hyperglycemia in Renal Transplantation

NCT01643382
View directory record Official record
Conditions
Diabetes, End Stage Renal Disease
Interventions
Insulin, Insulin, Asp(B28)-
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 23, 2026, 1:42 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Children With Diabetes at Risk for Heart Disease.

NCT02275091
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Complications
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
12 Years to 21 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 23, 2026, 1:42 PM EDT
Not listed Phase 2 Interventional

A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

NCT02312050
View directory record Official record
Conditions
Diabetic Chronic Kidney Disease
Interventions
GCS-100, Placebo
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years to 90 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
Chula Vista, California • El Centro, California • La Jolla, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.

NCT01464320
View directory record Official record
Conditions
Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine
Interventions
ABT-614, Placebo Comparator
Drug
Lead sponsor
Abbott
Industry
Eligibility
19 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

Development of NIC5-15 in the Treatment of Alzheimer's Disease

NCT00470418
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
NIC5-15, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 23, 2026, 1:42 PM EDT
Completed No phase listed Observational

Performance Evaluation of a Non-Invasive Glucose Monitor as Compared to CGM Data Acquired by the iPro2

NCT01831752
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
12 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 23, 2026, 1:42 PM EDT
Enrolling by invitation Not applicable Interventional

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

NCT07605390
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Epic-Based Clinician Notification, Usual Care
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 1:42 PM EDT
Completed No phase listed Observational

Identifying Risk for Diabetes and Heart Disease in Women

NCT01809288
View directory record Official record
Conditions
Obesity, Insulin Resistance, Triglycerides, Diabetes
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years to 65 Years · Female only
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Not applicable Interventional

Disease Management and Educational Intervention Outcomes in High-Risk Diabetics

NCT00012662
View directory record Official record
Conditions
Diabetes Mellitus Self Management Education, Hyperglycemic Control, High Risk Diabetes
Interventions
Diabetes Self Management Education
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
1
States / cities
Atlanta, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 4 Interventional

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

NCT01076842
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM
Drug · Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Not applicable Interventional Results available

Vitamin D Supplementation on Cardiovascular Risk Factors

NCT01412710
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Cholecalciferol
Drug
Lead sponsor
Florida International University
Other
Eligibility
30 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

NCT04308590
View directory record Official record
Conditions
Hypercortisolism
Interventions
Relacorilant, Placebo
Drug · Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
22
States / cities
Birmingham, Alabama • Stanford, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 2 Interventional

A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease

NCT01928420
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Drug: NIC5-15, Placebo
Drug
Lead sponsor
Humanetics Corporation
Industry
Eligibility
40 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 23, 2026, 1:42 PM EDT
Enrolling by invitation Not applicable Interventional

Testing a Multilevel, Culturally Appropriate Lifestyle Intervention For Hispanic Patients With Metabolic Dysfunction-associated Steatotic Liver Disease

NCT07199491
View directory record Official record
Conditions
Metabolic-dysfunction Associated Liver Disease (MASLD)
Interventions
Healthy Liver/Hígado Sano program, Usual Care
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 2 Interventional

Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

NCT00811889
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes, Diabetic Nephropathy
Interventions
Placebo, Bardoxolone Methyl (RTA 402)
Other · Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Birmingham, Alabama • Montgomery, Alabama • Chula Vista, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Amount and Type of Dietary Carbohydrates on Risk for Cardiovascular Heart Disease and Diabetes

NCT00608049
View directory record Official record
Conditions
Overweight, Cardiovascular Diseases
Interventions
High carbohydrate and low glycemic index (GI) diet, Low carbohydrate and low GI diet, High carbohydrate and high GI diet, Low carbohydrate and high GI diet
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 23, 2026, 1:42 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)

NCT05008276
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Adolescent Obesity, Pre Diabetes, Kidney Hypoxia, Puberty
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Dextran 40
Drug
Lead sponsor
Petter Bjornstad
Other
Eligibility
8 Years to 14 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)

NCT03751007
View directory record Official record
Conditions
Diabetes type1
Interventions
AG019 - Low Dose, Teplizumab, Placebo-AG019, Placebo-Teplizumab, AG019 - High Dose
Biological · Drug
Lead sponsor
Precigen Actobio T1D, LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Ventura, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Not applicable Interventional

EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis

NCT03650712
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes
Interventions
Oral glucose tolerance test, Continuous glucose monitoring, Dexa scan
Diagnostic Test
Lead sponsor
Katie Larson Ode
Other
Eligibility
6 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Iowa City, Iowa • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 1:42 PM EDT
Recruiting Phase 4 Interventional

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

NCT02915198
View directory record Official record
Conditions
Prediabetic State, Atherosclerosis, Metformin
Interventions
Metformin XR, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
7,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Not applicable Interventional

Undiagnosed Diabetes in a Dental Setting

NCT01711385
View directory record Official record
Conditions
Prediabetic State, Type 2 Diabetes Mellitus With Oral Complications, Periodontal Pocket, Tooth Loss
Interventions
Enhanced intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
30 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 23, 2026, 1:42 PM EDT